Right to Try has given patients with life-threatening illnesses a pathway to access investigational drugs after approved options and clinical trials have been exhausted. It was a meaningful step forward, but science has moved faster than the law.
Today, treatment can be matched to a patient’s unique biology. Through functional precision oncology, physicians can use tools and technology that test a patient’s own living tumor cells against a wide panel of therapies, alongside AI-enabled software that provides data to the physician, identifying and prioritizing options based on ex vivo drug testing. This is exactly how we believe Right to Try should evolve, because better-informed drug selection doesn’t add risk. It lowers it. If you’d like to know more about the proposed language or provide a letter of support, please click the links below.
Two Page Overview of the Right To Try Amendment